Notwithstanding encouraging clinical results, copyright's Vyndamax, a treatment for hereditary website transthyretin-mediated amyloidosis (hATTR), is experiencing substantial resistance from pharmacy benefit managers. The insurers are typically creating limitations to access, like high expense restrictions and prior authorization that hinder patien